Novartis and Biogen pull out of neuro drug partnerships with Sangamo
Sangamo lost two big-name partners in the span of a few days, after Novartis and Biogen pulled out of their partnerships with the biotech company.
Biogen signed up in February 2020 to partner up with Sangamo on the search for new gene regulation therapies to treat neurological disorders, paying $350 million upfront plus an equity investment for access to Sangamo’s zinc finger proteins. The Novartis collaboration, with a $75 million upfront, followed a few months later, similarly focused on neurodevelopmental disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.